Oslo, Norway, November 17, 2021 - Vaccibody AS, a clinical-stage
biopharmaceutical company dedicated to the discovery and development of vaccines
and novel immunotherapies, today announced its third quarter 2021 results.

The third quarter 2021 report will be available at
https://www.vaccibody.com/financial-reports-and-presentations/ 


Contact for Vaccibody:
CEO Michael Engsig
Vaccibody AS
info@vaccibody.com  


About Vaccibody 
Vaccibody, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Vaccibody's modular vaccine
technology specifically targets antigens to Antigen Presenting Cells, which are
essential for inducing rapid, strong and long-lasting antigen specific immune
responses and elicit efficacious clinical responses. 

Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment
of human papilloma virus 16 induced malignancies which is in Phase 2 for the
treatment of cervical cancer